RxDoctor Payments Data

Jessica Maganda, NP

Acute Care · Burbank, CANPI 1063921088

Payments from drug & device makers

$1,158in general payments, 2019–2025

Across 28 payments — averaging $41.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$275
  • Bard Access Systems, Inc.$154
  • Medtronic$152
  • AstraZeneca$139
  • Lexicon Pharmaceuticals, Inc.$130
  • Boehringer Ingelheim$89
  • plus $217 from 6 others

What the payments were for

  • Food & beverage$1,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,158 in reported general payments places this provider in the 75th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$9,799
Medicare patients
60
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin85$102,352
EntrestoSacubitril/Valsartan34$48,953
OzempicSemaglutide23$23,073
EliquisApixaban14$22,941
FarxigaDapagliflozin Propanediol15$16,731
Losartan Potassium62$658
Atorvastatin Calcium33$648
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide38$529
Chlorthalidone27$361
Rosuvastatin Calcium11$351
Amlodipine Besylate27$219
Metoprolol Succinate12$162
Metoprolol Tartrate33$148
Furosemide31$83
Hydrochlorothiazide11$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$89$102,35285 claims
NovartisEntresto$19$48,95334 claims
Novo NordiskOzempic$275$23,07323 claims
AstraZenecaFarxiga$139$16,73115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,153 acute care providers in California.

Other acute care in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →